Literature DB >> 10466859

Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma.

H Schouwink1, C M Korse, J M Bonfrer, A A Hart, P Baas.   

Abstract

In malignant mesothelioma, survival is claimed to be related to age, duration of symptoms, performance status, histological subtype, stage and platelet count. However the exact prognostic value of these factors is still a matter of debate. We studied the two cytokeratin markers, Cyfra 21-1 and Tissue polypeptide antigen (TPA) for their significance in predicting survival retrospectively in 52 patients. Cyfra 21-1 and TPA were elevated in 26 (50%) and 30 (58%) patients, respectively, and were highly correlated (r = 0.98). Univariate analysis of data from 51 patients, showed a relation with survival for performance status (P = 0.010), thoracic pain (P = 0.014), platelet count (P = 0.027), Cyfra 21-1 (P = 0.002) and TPA (P = 0.003). Multivariate analysis identified independent prognostic significance for performance status, platelet count and Cyfra 21-1. In addition to performance status ( < 80 vs. > 80) the cytokeratin markers identified patients with good prognosis in a log rank test. Values of Cyfra 21-1 and TPA are significantly correlated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10466859     DOI: 10.1016/s0169-5002(99)00044-6

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  10 in total

1.  Biomarkers and prognostic factors for mesothelioma.

Authors:  Harvey I Pass
Journal:  Ann Cardiothorac Surg       Date:  2012-11

2.  Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma.

Authors:  Aki Murakami; Chiharu Tabata; Rie Tabata; Hisaya Okuwa; Takashi Nakano
Journal:  Oncol Lett       Date:  2011-12-23       Impact factor: 2.967

3.  Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma.

Authors:  Abdullah Cetin Tanrikulu; Abdurrahman Abakay; Halil Komek; Ozlem Abakay
Journal:  Environ Health Prev Med       Date:  2016-04-11       Impact factor: 3.674

Review 4.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

5.  Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma.

Authors:  Kazuya Fukuoka; Kozo Kuribayashi; Shusai Yamada; Kunihiro Tamura; Chiharu Tabata; Takashi Nakano
Journal:  Mol Clin Oncol       Date:  2013-09-02

6.  Angiogenesis is an independent prognostic factor in malignant mesothelioma.

Authors:  J G Edwards; G Cox; A Andi; J L Jones; R A Walker; D A Waller; K J O'Byrne
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

7.  Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring.

Authors:  Ferdinando Cerciello; Meena Choi; Annalisa Nicastri; Damaris Bausch-Fluck; Annemarie Ziegler; Olga Vitek; Emanuela Felley-Bosco; Rolf Stahel; Ruedi Aebersold; Bernd Wollscheid
Journal:  Clin Proteomics       Date:  2013-11-08       Impact factor: 3.988

Review 8.  Prognostication and monitoring of mesothelioma using biomarkers: a systematic review.

Authors:  David T Arnold; Duneesha De Fonseka; Fergus W Hamilton; Najib M Rahman; Nick A Maskell
Journal:  Br J Cancer       Date:  2017-02-07       Impact factor: 7.640

9.  Three tumor markers for improved efficacy in the management of patients with malignant pleural mesothelioma.

Authors:  Akifumi Nakamura; Teruhisa Takuwa; Masaki Hashimoto; Ayumi Kuroda; Toru Nakamichi; Seiji Matsumoto; Nobuyuki Kondo; Takashi Kijima; Seiki Hasegawa
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

10.  Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application.

Authors:  Marco Tomasetti; Lory Santarelli
Journal:  Cancers (Basel)       Date:  2010-04-14       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.